India: Carlyle ties ups with Viyash for generics platform

FILE PHOTO: The logo of the Carlyle Group is displayed at the company's office in Tokyo, Japan October 17, 2018. REUTERS/Issei Kato

Global investment firm Carlyle and pharmaceutical professionals Dr Hari Babu and Dr Srihari Raju Kalidindi, founder and co-founder of Viyash Life Sciences Pvt Ltd on Tuesday said that CA Hull Investments, an affiliated entity of Carlyle and Viyash have established an integrated generic pharmaceutical platform in India.

Viyash was set-up by Dr. Hari Babu in partnership with Dr. Srihari Raju Kalidindi. Viyash is a  manufacturer of API (active pharmaceutical ingredients) intermediates with a strategy to consolidate other pharma intermediates, API and formulation assets to create an integrated offering for large generics customers. Babu was previously Global COO of multinational pharmaceutical company Mylan and CEO of Mylan India, while Kalidindi co-founded and was previously the Executive Director of Indian pharmaceutical company Laurus Laboratories.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter